📗 Cite This Artifact
mds-2026-advanced-neuroimaging
MDS 2026 — Advanced Neuroimaging in Movement Disorders
Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders
Overview
Advanced neuroimaging plays a critical role in the diagnosis, differential diagnosis, and disease monitoring of Parkinson's disease (PD) and related movement disorders. MDS 2026 will showcase significant advances in neuroimaging techniques, from established dopamine transporter imaging to emerging molecular probes targeting pathological alpha-synuclein.
This page covers the key neuroimaging topics expected at MDS 2026:
- Dopamine transporter (DAT) imaging (SPECT/PET)
- Neuromelanin-sensitive MRI
- Emerging PET tracers for alpha-synuclein and tau pathology
- Advanced MRI techniques for differential diagnosis
Dopamine Transporter Imaging
Background
Dopamine transporter imaging using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) is a cornerstone of movement disorder diagnostics. DAT scans visualize presynaptic dopamine reuptake sites, providing objective evidence of nigrostriatal dopaminergic degeneration[@bajaj2020].
The most widely used radiotracer is I-123 ioflupane (DaTscan/FP-CIT), which received FDA approval in 2011 for differentiating parkinsonian syndromes from essential tremor. This imaging modality has a sensitivity of 90-95% and specificity of 80-90% for detecting dopaminergic deficits[@arena2020].
MDS 2026 — Advanced Neuroimaging in Movement Disorders
Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders
Overview
Advanced neuroimaging plays a critical role in the diagnosis, differential diagnosis, and disease monitoring of Parkinson's disease (PD) and related movement disorders. MDS 2026 will showcase significant advances in neuroimaging techniques, from established dopamine transporter imaging to emerging molecular probes targeting pathological alpha-synuclein.
This page covers the key neuroimaging topics expected at MDS 2026:
- Dopamine transporter (DAT) imaging (SPECT/PET)
- Neuromelanin-sensitive MRI
- Emerging PET tracers for alpha-synuclein and tau pathology
- Advanced MRI techniques for differential diagnosis
Dopamine Transporter Imaging
Background
Dopamine transporter imaging using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) is a cornerstone of movement disorder diagnostics. DAT scans visualize presynaptic dopamine reuptake sites, providing objective evidence of nigrostriatal dopaminergic degeneration[@bajaj2020].
The most widely used radiotracer is I-123 ioflupane (DaTscan/FP-CIT), which received FDA approval in 2011 for differentiating parkinsonian syndromes from essential tremor. This imaging modality has a sensitivity of 90-95% and specificity of 80-90% for detecting dopaminergic deficits[@arena2020].
Key Advances Expected at MDS 2026
MDS 2026 will highlight several developments in DAT imaging:
- New F-18 DAT ligands with improved kinetics and spatial resolution
- Earlier detection of dopaminergic deficits in prodromal PD
- Reduced radiation exposure compared to I-123 SPECT
- Machine learning algorithms for automated classification
- Standardized striatal binding ratio (SBR) protocols
- Longitudinal progression modeling
- Disease-modifying therapy trial endpoints
- Deep brain stimulation surgical planning
- Differential diagnosis of parkinsonian syndromes
Clinical Utility in PD
Pattern Recognition
| Disorder | DAT Scan Pattern | Key Features |
|----------|-----------------|--------------|
| Parkinson's Disease | Asymmetric reduction | Putamen worse than caudate |
| Dementia with Lewy Bodies | Diffuse reduction | Caudate and putamen equally affected |
| Progressive Supranuclear Palsy | Moderate diffuse | Less severe than PD |
| Multiple System Atrophy | Variable/asymmetric | Mixed pattern |
| Corticobasal Degeneration | Asymmetric | Often unilateral |
Disease Monitoring
DAT imaging provides valuable information for tracking disease progression:
- Annual SBR decline: Approximately 4-6% in PD patients
- Faster decline correlates with worse prognosis
- Therapeutic monitoring: Disease-modifying therapies may slow the decline
- Clinical trial endpoints: Objective biomarker for neuroprotective trials
See [DAT Scan Imaging](/mechanisms/dat-scan-imaging) for detailed technical information.
Neuromelanin-Sensitive MRI
Background
Neuromelanin-sensitive MRI (NM-MRI) is a specialized technique that detects the paramagnetic signal from neuromelanin — a black pigment synthesized in catecholaminergic neurons of the substantia nigra pars compacta (SNpc) and locus coeruleus (LC)[@sasaki2014]. This non-invasive technique provides direct visualization of neuromelanin-containing neurons, which degenerate in Parkinson's disease.
Neuromelanin has unique properties:
- Paramagnetic: Contains iron and oxidized polyphenol complexes
- T1 hyperintensity: Produces bright signal on T1-weighted images
- Selectivity: Specific to catecholaminergic neurons
- Age-dependent: Accumulates with age, declines with neurodegeneration
Key Advances Expected at MDS 2026
- Standardized signal-to-noise ratio (SNR) metrics
- Binding ratio calculations
- Volume loss assessment
- Distinguishing PD from atypical parkinsonisms
- PSP shows more severe locus coeruleus involvement than PD
- MSA patterns differ from PD[@ohtsuka2014]
- Early detection before DAT abnormalities
- Disease progression monitoring
- Correlation with motor and non-motor symptoms
Clinical Findings
| Metric | Parkinson's Disease | Clinical Correlation |
|--------|---------------------|---------------------|
| Substantia Nigra SNR | ↓↓ (30-50% reduction) | Motor severity (UPDRS) |
| Locus Coeruleus SNR | ↓↓ | Non-motor symptoms (depression, autonomic) |
| Binding Ratio | Reduced | Disease duration |
| Laterality | Asymmetric | Matches clinical symptoms |
Technical Parameters
- Field strength: 3T (7T provides superior resolution)
- Voxel size: 0.5-1mm isotropic (ideally)
- Sequence: 3D gradient echo (GRE) for T1 weighting
- Scan time: 10-20 minutes
- Key sequences: T1-weighted, T2* weighted, magnetization transfer
See [Neuromelanin Magnetic Resonance Imaging](/diagnostics/neuromelanin-magnetic-resonance-imaging) for detailed technical information.
Emerging PET Tracers for Alpha-Synuclein
Background
One of the most significant challenges in movement disorder neuroimaging is the development of PET tracers that can visualize alpha-synuclein pathology in vivo. While amyloid and tau PET tracers are established, alpha-synuclein PET remains an active area of research.
Key Advances Expected at MDS 2026
MDS 2026 will likely showcase progress in several areas:
- First-generation tracers showing promise in clinical studies
- Validation against histopathology
- Differential binding in synucleinopathies vs. tauopathies
- Simultaneous detection of alpha-synuclein, tau, and amyloid
- PET-MRI integration for structural-functional correlation
- Early diagnosis before motor symptoms
- Disease staging and progression monitoring
- Therapeutic target engagement
Current Research Status
| Tracer Type | Target | Status | Challenges |
|-------------|--------|--------|------------|
| First-generation α-syn | α-syn aggregates | Early clinical | Specificity vs. off-target |
| Optimized ligands | Conformational variants | Preclinical | Strain specificity |
| Dual-function | α-syn + dopamine | Research | Signal interpretation |
Comparison with Other PET Tracers
| Modality | Target | Clinical Use | Availability |
|----------|-------|--------------|--------------|
| Amyloid PET | β-amyloid plaques | AD diagnosis | Approved |
| Tau PET | Tau neurofibrillary tangles | AD, PSP staging | Approved |
| DAT PET | Presynaptic terminals | PD diagnosis | Approved |
| α-syn PET | Synuclein aggregates | Research | Investigational |
Advanced MRI Techniques
Diffusion Tensor Imaging (DTI)
Diffusion Tensor Imaging (DTI) is a powerful MRI technique that assesses white matter integrity by measuring the directional diffusion of water molecules in brain tissue. In Parkinson's disease, DTI can detect microstructural changes in prodromal stages and track disease progression[@gagliardi2019].
Technical Parameters:
- Diffusion directions: 30-90 directions recommended for clinical use
- b-values: 1000-2000 s/mm² typical
- FA threshold: FA < 0.3 often indicates abnormal white matter
- MD cutoff: Mean diffusivity > 1.0 × 10⁻³ mm²/s often indicates pathology
- Reduced fractional anisotropy (FA) in specific white matter pathways
- Increased mean diffusivity (MD) in substantia nigra
- Prodromal marker identification in individuals with RBD
- Correlation with disease severity and progression rate
- Machine learning-based DTI analysis for automated diagnosis
- Longitudinal DTI endpoints for clinical trials
- White matter network disruption patterns in PD subtypes
See [Diffusion Tensor Imaging in Neurodegeneration](/mechanisms/diffusion-mri-dti-neurodegeneration) and [Diffusion Tensor Imaging Diagnostics](/diagnostics/diffusion-tensor-imaging-neurodegeneration) for detailed technical information.
Diffusion Kurtosis Imaging (DKI)
Diffusion Kurtosis Imaging (DKI) is an advanced diffusion technique that goes beyond DTI by characterizing non-Gaussian water diffusion. This provides more sensitive measures of microstructural complexity than DTI alone[@wu2011].
Advantages over DTI:
- Higher sensitivity to tissue microstructure
- Better characterization of complex fiber architectures
- Reduced partial volume effects
- Improved detection of early changes in neurodegenerative diseases
- More sensitive detection of nigrostriatal degeneration than DTI alone
- Differentiation of PD from atypical parkinsonisms
- Assessment of cognitive impairment in PD
- Monitoring disease progression with higher sensitivity
Quantitative Susceptibility Mapping (QSM)
Quantitative Susceptibility Mapping (QSM) quantifies magnetic susceptibility variations in brain tissue, providing excellent contrast for iron deposition, calcification, and myelin content[@wang2019].
Clinical Relevance in PD:
- Elevated iron in substantia nigra pars compacta (SNpc)
- Correlation with disease severity (UPDRS scores)
- Differentiation from atypical parkinsonisms
- Tracking disease progression
| Region | Healthy Controls | Parkinson's Disease | Clinical Correlation |
|--------|-----------------|-------------------|---------------------|
| SNpc susceptibility | 50-100 ppb | 150-300 ppb | Motor severity |
| Red nucleus | 30-60 ppb | 60-120 ppb | Disease duration |
| Globus pallidus | 20-50 ppb | 40-80 ppb | Cognitive status |
MDS 2026 Advances:
- Automated QSM analysis pipelines
- Multi-parametric approaches combining QSM with R2* relaxometry
- Iron quantification for deep brain stimulation planning
Magnetization Transfer Imaging (MTI)
Magnetization Transfer Imaging (MTI) and Magnetization Transfer Ratio (MTR) assess macromolecular content in brain tissue, providing indirect measures of myelin integrity and axonal density[@fang2020].
Clinical Applications:
- Myelin loss detection in white matter
- Nigrostriatal pathway integrity assessment
- Differentiation of PD from MSA
- Disease progression monitoring
- Off-resonance saturation pulses (typically 1-10 kHz offset)
- MTR values expressed as percentage signal loss
- Lower MTR indicates demyelination or axonal loss
Resting-State Functional MRI (rs-fMRI)
Resting-state fMRI measures spontaneous brain activity and functional connectivity in the absence of task performance. In PD, characteristic patterns of connectivity changes correlate with motor and non-motor symptoms[@davis2016].
Key Networks Affected in PD:
- Default Mode Network (DMN): Altered connectivity in PD with cognitive impairment
- Motor Network: Reduced sensorimotor cortex connectivity
- Salience Network: Abnormal anterior cingulate connectivity
- Frontoparietal Network: Changes associated with executive dysfunction
- Disease staging based on network disruption patterns
- Cognitive impairment prediction
- Differential diagnosis (PD vs. atypical parkinsonisms)
- Treatment response monitoring (levodopa, DBS)
- Connectome-based classification algorithms
- Longitudinal connectivity studies
- Integration with transcranial magnetic stimulation
Arterial Spin Labeling (ASL)
Arterial Spin Labeling (ASL) is a non-contrast perfusion MRI technique that uses magnetically labeled arterial blood water as an endogenous tracer to quantify cerebral blood flow (CBF)[@ferreira2019].
Technical Parameters:
- Labeling duration: 1.5-2.0 seconds
- Post-labeling delay: 1.0-2.5 seconds
- PLD adjustment: Critical for accurate CBF in PD patients
- Typical values: 40-60 mL/100g/min gray matter
- Reduced perfusion in specific brain regions
- Disease progression monitoring
- Differentiation from healthy controls
- Correlation with motor and cognitive symptoms
| Region | Perfusion Change | Clinical Relevance |
|--------|-----------------|---------------------|
| Posterior cingulate | ↓ 15-25% | Cognitive impairment |
| Prefrontal cortex | ↓ 10-20% | Executive dysfunction |
| Occipital cortex | ↓ 10-15% | Visual hallucinations |
| Brainstem | ↓ 10-30% | Motor severity |
Magnetic Resonance Spectroscopy (MRS)
Magnetic Resonance Spectroscopy (MRS) provides metabolic information from specific brain regions without radiation exposure. Key metabolites assessed include N-acetylaspartate (NAA), choline, creatine, and lactate[@groger2014].
Key Metabolites:
- NAA: Neuronal viability marker — reduced in neurodegeneration
- Choline: Cell membrane turnover — elevated in demyelination
- Creatine: Energy metabolism reference
- Lactate: Indicates metabolic stress
- Glutamate/GABA: Neurotransmitter assessment
- Substantia nigra metabolite changes
- Differentiation of PD from atypical parkinsonisms
- Cognitive impairment correlation
- Treatment response monitoring
- Advanced 7T MRS applications
- Multi-voxel MRS for network-level analysis
- Machine learning integration with MRS data
Multi-Parametric MRI Approaches
The future of neuroimaging in movement disorders lies in multi-parametric approaches that combine multiple MRI techniques for comprehensive assessment[@ravan2019].
Integrated Protocol:
Advantages:
- Comprehensive characterization of disease
- Improved diagnostic accuracy
- Better correlation with clinical measures
- Multi-dimensional endpoint for clinical trials
- Standardized multi-parametric protocols
- Automated analysis pipelines
- Integration with AI/ML for diagnosis
- Multi-center validation studies
Integration with Clinical Practice
Diagnostic Algorithm
Role in Treatment Decisions
- Confirms degenerative vs. non-degenerative parkinsonism
- Guides treatment approach
- Disease severity assessment
- Progression expectations
- Baseline for disease progression tracking
- Clinical trial biomarker
MDS 2026 Session Highlights
Expected Topics
MDS 2026 neuroimaging sessions will likely cover:
Key Presenters
- Movement disorder neurologists specializing in neuroimaging
- Nuclear medicine physicians
- MRI physicists
- Clinical trial researchers
Related Pages
Neuroimaging
- [Neuroimaging in Neurodegenerative Diseases](/diagnostics/neuroimaging)
- [DAT Scan Imaging](/mechanisms/dat-scan-imaging)
- [Neuromelanin Magnetic Resonance Imaging](/diagnostics/neuromelanin-magnetic-resonance-imaging)
Parkinson's Disease
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Parkinson's Disease Diagnostics & Biomarkers — MDS 2026](/events/mds-2026-parkinsons-diagnostics-biomarkers)
Related Disorders
- [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
Other MDS 2026 Pages
- [MDS 2026 — Main Page](/events/mds-2026)
- [MDS 2026 — Parkinson's Disease Sessions](/events/mds-2026-parkinsons-sessions)
- [MDS 2026 — Parkinson's Disease Diagnostics & Biomarkers](/events/mds-2026-parkinsons-diagnostics-biomarkers)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | events-mds-2026-advanced-neuroimaging |
| kg_node_id | None |
| entity_type | general |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-f8bc573108bc |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'events-mds-2026-advanced-neuroimaging'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-events-mds-2026-advanced-neuroimaging?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[mds-2026-advanced-neuroimaging](http://scidex.ai/artifact/wiki-events-mds-2026-advanced-neuroimaging)
http://scidex.ai/artifact/wiki-events-mds-2026-advanced-neuroimaging